Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics with a $60 price target after traveling with management. Despite the recent share performance, new money investment in this name, "even in the teeth of the current trend," may make sense, Raymond tells investors in a research note. The analyst thinks the company's September 13 FDA panel meeting for AR101 in peanut allergy "could serve as the catalyst to break the stock's downward trend." Further, Raymond feels "increasingly confident" in a "strong" commercial launch for AR101. Investors "who can look past the scary technicals can be rewarded here," he says.